Array BioPharma, Inc. Initiates Clinical Trial in Type 2 Diabetic Patients

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has dosed its first Type 2 diabetic patient in a Phase 1 clinical trial with its novel small molecule glucokinase activator (GKA), ARRY-403. In preclinical studies, ARRY-403 demonstrated effective control of both fasting and non-fasting blood glucose concentrations. The GKA activity of ARRY-403 was shown to be highly dependent on blood glucose concentrations. In the Phase 1 trial, the compound will be evaluated in single- and multiple-dose escalation studies in Type 2 diabetic patients. The study is designed to evaluate safety, tolerability, exposure and blood glucose control.

Back to news